References
- Cheifitz R. Lipid, statins and cardiovascular risk (Letter). Climacteric 2008; 11: 347–348
- Rosano G M, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9(Suppl 1)19–27
- Rosano G MC, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 2007; 10(Suppl 1)19–24
- Vitale C, Miceli M, Rosano G MC. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric 2007; 10(Suppl 2)16–20
- Sever P S, Dahlöf B, Poulter N R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158
- Mizuno K, Nakaya N, Ohashi Y, et al. for the MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA Study). Circulation 2008; 117: 494–502
- Fourth Joint Task Force of the Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on Cardiovascular Disease in Clinical Practice: Executive Summary. Eur J Cardiovascular Prevention Rehabilitation 2007; 14(Suppl 2)E1–40
- Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in perimenopausal women: a consensus statement of European cardiologists and gynecologists. Climacteric 2007; 10: 508–526, (Reproduced from Eur Heart J 2007;28: 2028–40)